Novavax Expands Large-Scale Global Manufacturing To Create More Doses Of COVID-19 Vaccine Candidate

GAITHERSBURG, Md. (WJZ) -- Gaithersburg-based Novavax is expanding to create more doses of its COVID-19 vaccine candidate.

The company just started human trials in Australia, and now, its buying a facility in the Czech Republic for $167 million. The facility could create an additional one billion doses starting next year.

CORONAVIRUS COVERAGE:

The vaccine, created by Novavax, showed promising results in animal studies. We're expected to learn how the first phase of human trials went this July.

If all goes well, phase two will expand to several countries.

For the latest information on coronavirus go to the Maryland Health Department's website or call 211. You can find all of WJZ's coverage on coronavirus in Maryland here.

Read more
f

We and our partners use cookies to understand how you use our site, improve your experience and serve you personalized content and advertising. Read about how we use cookies in our cookie policy and how you can control them by clicking Manage Settings. By continuing to use this site, you accept these cookies.